Vytorin Study to Get FDA Review

Once we fully review the data, we may consider whether any further action is required, and whether this has any effect on our way of approving cholesterol-lowering drugs. The FDA says it will explore the medical mystery of why Vytorin cuts cholesterol but doesn't seem to reduce plaque in the arteries. via WebMD Health News

[steve matrai]

is it possible that somehow the body knows, maybe due to other indicators from the food ingested, it is not absorbing the cholesterol it should so as a defense, it keeps the plaque stored tight.

[ayr2]

Important information about drug safety at www.adverse-drug-reaction.net